aTyr Pharma completes Phase 3 sarcoidosis trial enrollment; Q2 cash $81.4M

aTYR PHARMA INC

2024-Q2 EPS reported -$0.46 revenue$235,000

Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolled 268 patients; topline data expected Q3 2025.
Cash, equivalents, restricted cash and investments totaled $81.4M as of June 30, 2024.
R&D expenses $14.0M, G&A $3.3M for Q2 2024.
Phase 2 EFZO-CONNECT for SSc-ILD enrolling; interim data expected Q2 2025.
Appointed Jayant Aphale VP Technical Operations; research agreement with Stanford for anti-NRP2 in GBM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.